Systemic Lupus Erythematosus pipeline

Jul 22, 2026

Summary SLE is a chronic autoimmune disease affecting multiple organs, with ~936K diagnosed cases across the 7MM in 2025 and expected growth by 2036. BENLYSTA (belimumab, GSK) remains the cornerstone biologic, targeting BLyS to reduce autoreactive B cells; it expanded into lupus nephritis, pediatrics, and mu...

Jul 21, 2026

Summary Systemic lupus erythematosus, once considered highly unpredictable and difficult to treat, is undergoing a major therapeutic transformation driven by biologics, small molecules, and cell-based therapies. The SLE market is valued at around USD 3 billion in 2025 across the 7MM and is projected to grow ...

May 29, 2026

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2025, it was estimated that around 512,000 individuals in the United States were living with SLE, as per DelveInsight analysis, with new treatments for SLE urgently needed as 40% of treated SLE patien...